Skip to search formSkip to main content

177Lu-PSMA-617

Known as: 177Lu-617-prostate-specific membrane antigen ligand 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2017
Highly Cited
2017
177Lu-labeled PSMA-617 is a promising new therapeutic agent for radioligand therapy (RLT) of patients with metastatic castration… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Is this relevant?
2017
2017
The aim of this study was to develop a treatment protocol for 225Ac-PSMA-617 α-radiation therapy in advanced-stage, metastatic… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Is this relevant?
2017
2017
PurposeRadioligand therapies targeting prostate-specific membrane antigen (PSMA) have been established for the treatment of… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2017
2017
AimOur aim was to evaluate overall survival and parameters prognosticating longer survival in a large and homogeneous group of… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
2017
2017
BACKGROUND Various trivalent radiometals are well suited for labeling of DOTA-conjugated variants of Glu-ureido-based prostate… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
2017
2017
PurposeRadioligand therapy (RLT) using Lutetium-177 labeled PSMA-617 (Lu-PSMA) ligand is a new therapeutic option for salvage… Expand
  • table 1
  • figure 1
  • figure 3
  • figure 2
Is this relevant?
2017
2017
INTRODUCTION Recent successes in the treatment of metastatic castration-resistant prostate cancer (mCRPCa) by systemic… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • table 1
Is this relevant?
2016
2016
PurposeThe purpose of this study was to evaluate the efficacy and safety of a novel theranostic agent, 177Lu-DKFZ-PSMA-617… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
2016
2016
AIM The prostate-specific membrane antigen (PSMA) is a cell surface protein, which is overexpressed in nearly all cases of… Expand
Is this relevant?
Highly Cited
2015
Highly Cited
2015
PurposeDosimetry is critical to achieve the optimal therapeutic effect of radioligand therapy (RLT) with limited side effects… Expand
  • table 1
  • figure 1
  • table 2
  • table 3
  • figure 2
Is this relevant?